A Randomized, Double-blind, Multicentre, Phase II Controlled Trial Assessing ZACTIMATM (Vandetanib) Against Placebo in Prolonging the Off-treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007713/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine whether treatment with Zactima for up to 18 months
will prolong the off-treatment interval in patients who are undergoing intermittent androgen
deprivation therapy.
提供机构：
Vivli
创建时间：
2022-02-10
